6 completed, 2 withdrawn, 1 terminated. 7 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Withdrawn 2, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
Follow GTx-024: new trials by email Literature Review of GTx-024 trials Research Report on GTx-024
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence GTx-024 - Stress Urinary Incontinence | Phase 2 | Withdrawn | GTx | 2018-06-28 | 2024-03-01 | |
| Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence GTx-024, Matching Placebo - Stress Urinary Incontinence | Phase 2 | Withdrawn | GTx | 2018-05-28 | 2023-09-14 | |
| Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Enobosarm, Laboratory Biomarker Analysis, Pembrolizumab - Androgen Receptor Positive, Estrogen Receptor Negative | Phase 2 | Completed | City of Hope Medical Center | 18 | 2017-06-01 | 2024-02-20 |
| GTx-024 as a Treatment for Stress Urinary Incontinence in Women GTx-024 - Stress Urinary Incontinence | Phase 2 | Completed | GTx | 19 | 2016-01-01 | 2021-02-01 |
| Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer GTx-024 - ER+ and AR+ Breast Cancer | Phase 2 | Completed | GTx | 136 | 2015-08-01 | 2020-12-09 |
| Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) GTx-024 - Triple Negative Breast Cancer | Phase 2 | Terminated | GTx | 32 | 2015-06-01 | 2020-11-18 |
| Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum GTx-024, placebo - Muscle Wasting, Non-Small Cell Lung Cancer | Phase 3 | Completed | GTx | 330 | 2011-07-01 | 2020-11-09 |
| Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) GTx-024, placebo - Muscle Wasting, Non Small Cell Lung Cancer | Phase 3 | Completed | GTx | 321 | 2011-07-01 | 2016-03-03 |
| Study of GTx-024 on Muscle Wasting (Cachexia) Cancer. GTx-024, Placebo - Cachexia | Phase 2 | Completed | GTx | 159 | 2007-05-01 | 2014-07-11 |
Carcinoma, Non-Small-Cell Lung (3) · Muscular Atrophy (3) · Urinary Incontinence, Stress (3) · Triple Negative Breast Neoplasms (2) · Cachexia (1) · Colorectal Neoplasms (1) · Lymphoma, Non-Hodgkin (1)
GTx (8) · City of Hope Medical Center (1)
United States (9) · Canada (1)
Kenneth Peters, MD (2) · Beth A Overmoyer, MD (1) · Hope S Rugo, MD (1) · Kenneth M. Peters, MD (1) · Yuan Yuan (1)